BPTH (Bio-Path Holdings) Cyclically Adjusted FCF per Share: $-153.18 (As of Mar. 2026)


What is Bio-Path Holdings Cyclically Adjusted FCF per Share?

Bio-Path Holdings BPTH +34.29% Cyclically Adjusted FCF per Share is $-153.18 as of Mar. 2026. The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Bio-Path Holdings's adjusted free cash flow per share for the three months ended in Mar. 2026 was $-0.004. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-153.18 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 4.40% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 2.10% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was -3.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Bio-Path Holdings was 4.40% per year. The lowest was -14.80% per year. And the median was -0.15% per year.

As of today (2026-07-04), Bio-Path Holdings's current stock price is $0.047. Bio-Path Holdings's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was $-153.18. Bio-Path Holdings's Cyclically Adjusted Price-to-FCF of today is .


Bio-Path Holdings  (OTCPK:BPTH) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Bio-Path Holdings Cyclically Adjusted FCF per Share Related Terms


Bio-Path Holdings Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Bio-Path Holdings's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bio-Path Holdings Cyclically Adjusted FCF per Share Chart

Bio-Path Holdings Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -193.42 -198.26 -197.85 -190.07 -172.97

Bio-Path Holdings Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -172.97 -166.64 -159.64 0.00 -153.18

BPTH vs VBIO, HEPA, AXIM: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Bio-Path Holdings's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bio-Path Holdings Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bio-Path Holdings's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Bio-Path Holdings's Cyclically Adjusted Price-to-FCF falls into.



Bio-Path Holdings Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Bio-Path Holdings's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.004/330.2130*330.2130
=-0.004

Current CPI (Mar. 2026) = 330.2130.

Bio-Path Holdings Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201603 -108.227 238.132 -150.076
201606 -102.227 241.018 -140.059
201609 -79.458 241.428 -108.679
201612 -67.125 241.432 -91.809
201703 -94.333 243.801 -127.768
201706 -99.080 244.955 -133.565
201709 -61.160 246.819 -81.824
201712 -82.407 246.524 -110.382
201803 -60.036 249.554 -79.440
201806 -60.929 251.989 -79.843
201809 -50.724 252.439 -66.352
201812 -37.735 251.233 -49.598
201903 -23.624 254.202 -30.688
201906 -15.709 256.143 -20.252
201909 -13.146 256.759 -16.907
201912 -13.944 256.974 -17.918
202003 -13.703 258.115 -17.531
202006 -18.811 257.797 -24.095
202009 -12.719 260.280 -16.136
202012 -12.000 260.474 -15.213
202103 -5.497 264.877 -6.853
202106 -7.624 271.696 -9.266
202109 -8.213 274.310 -9.887
202112 -7.824 278.802 -9.267
202203 -7.056 287.504 -8.104
202206 -11.740 296.311 -13.083
202209 -9.425 296.808 -10.486
202212 -13.089 296.797 -14.563
202303 -9.178 301.836 -10.041
202306 -8.259 305.109 -8.939
202309 -5.529 307.789 -5.932
202312 -2.959 306.746 -3.185
202403 -1.604 312.332 -1.696
202406 -2.002 314.175 -2.104
202409 -1.136 315.301 -1.190
202412 -0.499 315.605 -0.522
202503 -0.186 319.799 -0.192
202506 -0.034 322.561 -0.035
202509 0.000 324.800 0.000
202603 -0.004 330.213 -0.004

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of $-153.18 mean?
Bio-Path Holdings (BPTH) has a Cyclically Adjusted FCF per Share of $-153.18 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Bio-Path Holdings and its competitors.
Is Bio-Path Holdings' Cyclically Adjusted FCF per Share too high?
Bio-Path Holdings' current Cyclically Adjusted FCF per Share is $-153.18.
How does Bio-Path Holdings' Cyclically Adjusted FCF per Share compare to VBIO and HEPA?
Bio-Path Holdings' Cyclically Adjusted FCF per Share of $-153.18 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Bio-Path Holdings and its competitors. Bio-Path Holdings's current Cyclically Adjusted FCF per Share is $-153.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Path Holdings stock overvalued right now?
Bio-Path Holdings (BPTH) has a current Cyclically Adjusted FCF per Share of $-153.18. The current Cyclically Adjusted FCF per Share is $-153.18. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Bio-Path Holdings (BPTH), the current Cyclically Adjusted FCF per Share is $-153.18 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bio-Path Holdings Business Description

Address No. 2407, 625 Stanwix Street, Pittsburgh, PA, USA, 15222
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's drug candidate, prexigebersen, is in the efficacy portion of a Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. The other drugs of the company are BP1002, BP1003, BP1001-A, and DNABILIZE.